Skip to content
Open access

Mapping the Ligand Binding Landscape of Nurr1 (NR4A2): Computational Characterization of Small-Molecule Interactions in Alzheimer’s Disease Pathway

Sep 2026 · Scholarly Review Journal · 0 citations · 10 references

TL;DR

This project establishes a reproducible computational process for ligand and drug discovery, identifying multiple candidates for Nurr1, which, in the near future, can be put into practical testing grounds for validation and eventually clinical drug design.

Abstract

For a long time, Alzheimer’s disease has been among the most commonplace and fearsome neurodegenerative disorders worldwide. It is characterized by progressive cognitive decline caused by a combination of each-interacting molecular pathological processes. Despite decades of effort, therapeutic strategies targeting single mechanisms such as β-amyloid or tau pathologies have failed to achieve durable disease modification. This leads to recently increasingly relevant focus on multi-axis regulatory approaches. Nuclear receptor related 1 protein(Nurr1/NR4A2) has been under the microscope as a promising, key transcriptional regulator of neuroinflammation, neuronal survival, and even mitochondrial function. Stacking evidence shows Nurr1 inactivity to Alzheimer’s disease progression, providing grounds and necessity for this project to target it as a potential therapeutic. In this project, a comprehensive, fully computational framework was developed to map out the ligand-binding features of Nurr1. To start off, Geometric, energetic, and machine-learning-based methods were deployed to identify, through different means, binding pockets. Then, Pharmacophore modeling and mass virtual screenings were subsequently applied to predict various candidate small molecules from trusted public chemical libraries. Next, molecular docking simulations were performed using SwissDock to eventually reveal multiple ligands with the most favorable binding energies and stable clusterings within the previously spotted cavity. Administration of the potential drug is then tested using virtual ADME and toxicity profiling, filtering down to refined candidates of drugs with optimal affinity and no significant safety concerns. At the end, this project establishes a reproducible computational process for ligand and drug discovery, identifying multiple candidates for Nurr1, which, in the near future, can be put into practical testing grounds for validation and eventually clinical drug design.

Read PDF

Similar papers

Review Open access Aug 2026

Multi Target Directed Ligand for Alzheimer’s Disease: A Review of Therapeutic Strategies and Advances

Progress in the creation and design of Multi-target directed ligands have become a promising approach in the last few years, and recent advances in medicinal chemistry and structure-based design bolster the argument for MTDLs as next-generation therapeutic candidates, notwithstanding challenges like bioavailability and...

Sumesh Kumar, Vansh Sharma, Happy et al. · 0 citations
Review Sep 2026

Rivastigmine-centered molecular hybridization strategies for multi-targeted intervention in Alzheimer's disease: Advances (2020-2026).

This review comprehensively summarizes and critically analyzes advances reported from 2020 to 2026 in the design, synthesis, biological evaluation, and therapeutic potential of RIV-based hybrid molecules and scaffold modifications for AD treatment.

Nitin Kumar, V. Kushwaha, Gourav Singh et al. · 0 citations
Open access Jan 2026

Bioinformatics-Driven Discovery of Aβ-Targeted Therapeutics and Diagnostic Biomarkers for Alzheimer's Disease.

Three small molecules, resveratrol, curcumin, and apigenin, demonstrated strong binding affinities for NFKBIA, clarifying the priority candidate gene and feasible strategic directions, which are expected to be translated into practical pathways for precision diagnosis and treatment of AD.

Xin Li, Xue-Rong Liu, Xin-Ran Song et al. · 0 citations
Open access Aug 2026

Naringenin as a dual-target modulator of RAGE–NF-κB signaling and Aβ fibrillization in Alzheimer’s disease: integrated computational and experimental analyses

NAR reduced Aβ42-induced NF-κB activation in RAGE-positive C6 cells, protected SH-SY5Y neurons from Aβ42 toxicity, and inhibited Aβ42 fibrillization in vitro, producing non-seeding aggregates consistent with impaired fibril formation, and attenuated rotenone-induced α-synuclein-associated cellular stress.

Inderjeet Bhogal, I. Frydrych, Ajay Modi et al. · 0 citations
Open access Sep 2026

Fungal Metabolites as Multi-Target Modulators of Alzheimer’s Disease: An Integrated In Silico Docking and Molecular Dynamics Approach

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with limited therapeutic options offering only symptomatic relief. Natural fungal metabolites have recently gained attention for their neuroprotective potential. In this study, an extensive library of 18,349 fungal compounds was retrieved from the NPA...

Deepeesh Vijayan, K. Siva, Jayathraa Ramachandran et al. · 0 citations
Open access Sep 2026

Novel Pyrazoline Derivatives as Therapeutic Candidate for Alzheimer’s Disease: An Integrated Network Pharmacology and 3D-QSAR Modelling

Findings highlight APOE, BACE1, and CSF1R as key therapeutic targets as key therapeutic targets and identify compound 2a as a promising multi-target lead candidate for additional experimental validation in AD.

Md. Mainuddin Hossain, Towfika Rahman Singdha, Saifullah Sakib et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.